| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/15/2023 | — | Maxim Group | Downgrades | Buy → Hold | |
| 08/18/2023 | 1551.21% | Roth MKM | $14 → $13 | Maintains | Buy |
| 11/01/2021 | 1932.26% | Roth Capital | → $16 | Initiates Coverage On | → Buy |
| 10/06/2021 | 1805.25% | Maxim Group | → $15 | Initiates Coverage On | → Buy |
What is the target price for RenovoRx (RNXT)?
The latest price target for RenovoRx (NASDAQ: RNXT) was reported by Maxim Group on November 15, 2023. The analyst firm set a price target for $0.00 expecting RNXT to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for RenovoRx (RNXT)?
The latest analyst rating for RenovoRx (NASDAQ: RNXT) was provided by Maxim Group, and RenovoRx downgraded their hold rating.
When is the next analyst rating going to be posted or updated for RenovoRx (RNXT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of RenovoRx, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for RenovoRx was filed on November 15, 2023 so you should expect the next rating to be made available sometime around November 15, 2024.
Is the Analyst Rating RenovoRx (RNXT) correct?
While ratings are subjective and will change, the latest RenovoRx (RNXT) rating was a downgraded with a price target of $0.00 to $0.00. The current price RenovoRx (RNXT) is trading at is $0.79, which is out of the analyst's predicted range.